Dupilumab

Evidence indicates that dupilumab is acceptable to use during breastfeeding. Because dupilumab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Expert opinions consider dupilumab acceptable during breastfeeding.[3-5] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[6] Until more data become available, dupilumab should be used with caution while nursing a newborn or preterm infant.